Investing in NeoClone presents a unique opportunity to get involved with a privately-owned, maturing company that is poised for rapid growth. Our team of experienced scientists and business professionals have successfully developed and marketed excellent monoclonal antibodies developed with our proprietary NeoAb® process. We are continually adding products to our reagents portfolio as well as actively serving and collaborating in the diagnostics market.
We are also aggressively pursuing our ability to make fully-human antibodies from a de novo immune response that are qualified for therapeutic use. As we advance our abilities to make fully-human antibodies, NeoClone will be one of only a few companies that can help others bring these therapeutic products to market -- a market which is projected to reach $60 billion by 2014.
To learn more about investment opportunities, contact
our Chief Executive Officer.